NuVasive (NuVasive) Debt-to-Asset : 0.43 (As of Jun. 2023)

View and export this data going back to 2004. Start your Free Trial

What is NuVasive Debt-to-Asset?

NuVasive's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $361 Mil. NuVasive's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $545 Mil. NuVasive's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2023 was $2,090 Mil. NuVasive's debt to asset for the quarter that ended in Jun. 2023 was 0.43.

NuVasive Debt-to-Asset Historical Data

The historical data trend for NuVasive's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NuVasive Debt-to-Asset Chart

NuVasive Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

0.35

0.37

0.57

0.47

0.45

NuVasive Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Debt-to-Asset	Get a 7-Day Free Trial															0.46	0.46	0.45	0.46	0.43

Competitive Comparison of NuVasive's Debt-to-Asset

For the Medical Devices subindustry, NuVasive's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NuVasive's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NuVasive's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where NuVasive's Debt-to-Asset falls into.

NuVasive Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

NuVasive's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(458.075	+	548.008)	/	2224.505
	=	0.45

NuVasive's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(360.785	+	545.363)	/	2089.55
	=	0.43

NuVasive (NAS:NUVA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

NuVasive Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of NuVasive's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

NuVasive (NuVasive) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NuVasive Inc (NAS:NUVA) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

12101 Airport Way, Broomfield, CO, USA, 92121

Website

https://www.nuvasive.com

NuVasive Inc is a medical technology company focused on developing, manufacturing, selling and providing procedural solutions for spine surgery, with a guiding purpose to transform surgery, advance care and change lives. The company has a portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. It also develop and sell magnetically adjustable implant systems for spine and specialized orthopedic procedures.

Executives

Michael Farrington	officer: SVP, People and Culture	7475 LUSK BLVD., SAN DIEGO CA 92121
Marc W. Rosenbaum	officer: Chief Accounting Officer	7475 LUSK BLVD., SAN DIEGO CA 92121
James Christopher Barry	director, officer: Chief Executive Officer	7475 LUSK BLVD, SAN DIEGO CA 92121
Andrew C. Morton	officer: SVP, CHRO	10910 DOMAIN DRIVE, SUITE 300, AUSTIN TX 78758
Amy Belt Raimundo	director	ONE KAISER PLAZA, 22ND FLOOR, OAKLAND CA 94612
Lucas Vitale	officer: Chief Human Resources Officer	7475 LUSK BLVD, SAN DIEGO CA 92121
Massimo Calafiore	officer: EVP, Global Business Units	7475 LUSK BLVD., SAN DIEGO CA 92121
Siddhartha Kadia	director	7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Vickie L Capps	director	2985 SCOTT STREET, VISTA CA 92083
Brent J. Boucher	officer: EVP, Global Commercial	14 PLAZA DRIVE, LATHAM NY 12110
Matthew Link	officer: Exec. VP U.S. Sales	7475 LUSK BLVD, SAN DIEGO CA 92121
Matthew K Harbaugh	officer: EVP and CFO	675 MCDONNELL BLVD., HAZELWOOD MO 63042
Dale A. Wolf	officer: SVP, Global Operations	7475 LUSK BLVD., SAN DIEGO CA 92121
Gregory T Lucier	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Mcclintock	officer: President, U.S. Commercial	7475 LUSK BLVD, SAN DIEGO CA 92121